Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zhefeng Liu

Showing results (21-30 of 57) with videos related to

Pageof 6
Sort By:
Frontiers in Pharmacology|June 5, 2024
Comparative efficacy of six programmed cell death Protein-1 inhibitors as first-line treatment for advanced non-small cell lung cancer: a multicenter retrospective cohort studySiyuan Chen, Tao Li, Wenyu Yang, et al.
Frontiers in Neurology|April 18, 2024
Prognosis of immune checkpoint inhibitor-induced myasthenia gravis: a single center experience and systematic reviewYuhui Qin, Siyuan Chen, Qian Gui, et al.
Frontiers in Oncology|September 5, 2022
Evolutions in the management of non-small cell lung cancer: A bibliometric study from the 100 most impactful articles in the fieldSiyuan Chen, Yu Qiao, Juan Chen, et al.
Cancer Medicine|March 14, 2020
Crizotinib vs platinum-based chemotherapy as first-line treatment for advanced non-small cell lung cancer with different ROS1 fusion variantsHaiyan Xu, Quan Zhang, Li Liang, et al.
Neural Regeneration Research|September 11, 2014
Synergistic effects of elevated homocysteine level and abnormal blood lipids on the onset of strokeLu Hao, Liming Chen, Xiaoyong Sai, et al.
Therapeutic Advances in Medical Oncology|May 20, 2020
Association of immune-related pneumonitis with the efficacy of PD-1/PD-L1 inhibitors in non-small cell lung cancerPengfei Cui, Di Huang, Zhaozhen Wu, et al.
Clinical and Experimental Medicine|May 4, 2025
Mechanism of action and future perspectives of ADCs in combination with immune checkpoint inhibitors for solid tumorsYahui Lv, Xiaoran Cui, Tao Li, et al.
Targeted Oncology|February 14, 2020
Tumor Mutation Burden as a Potential Biomarker for PD-1/PD-L1 Inhibition in Advanced Non-small Cell Lung CancerDi Huang, Fan Zhang, Haitao Tao, et al.
Clinical Medicine Insights. Oncology|March 19, 2021
The Synergistic Effect of PARP Inhibitors and Immune Checkpoint InhibitorsZhaozhen Wu, Pengfei Cui, Haitao Tao, et al.
Cancer Immunology, Immunotherapy : CII|March 19, 2021
Efficacy and safety of anti-PD-1-based therapy in combination with PARP inhibitors for patients with advanced solid tumors in a real-world settingZhaozhen Wu, Haitao Tao, Sujie Zhang, et al.
Pageof 6

Showing results (21-30 of 57) with videos related to

Sort By:
Pageof 6
Frontiers in Pharmacology|June 5, 2024
Comparative efficacy of six programmed cell death Protein-1 inhibitors as first-line treatment for advanced non-small cell lung cancer: a multicenter retrospective cohort studySiyuan Chen, Tao Li, Wenyu Yang, et al.
Frontiers in Neurology|April 18, 2024
Prognosis of immune checkpoint inhibitor-induced myasthenia gravis: a single center experience and systematic reviewYuhui Qin, Siyuan Chen, Qian Gui, et al.
Frontiers in Oncology|September 5, 2022
Evolutions in the management of non-small cell lung cancer: A bibliometric study from the 100 most impactful articles in the fieldSiyuan Chen, Yu Qiao, Juan Chen, et al.
Cancer Medicine|March 14, 2020
Crizotinib vs platinum-based chemotherapy as first-line treatment for advanced non-small cell lung cancer with different ROS1 fusion variantsHaiyan Xu, Quan Zhang, Li Liang, et al.
Neural Regeneration Research|September 11, 2014
Synergistic effects of elevated homocysteine level and abnormal blood lipids on the onset of strokeLu Hao, Liming Chen, Xiaoyong Sai, et al.
Therapeutic Advances in Medical Oncology|May 20, 2020
Association of immune-related pneumonitis with the efficacy of PD-1/PD-L1 inhibitors in non-small cell lung cancerPengfei Cui, Di Huang, Zhaozhen Wu, et al.
Clinical and Experimental Medicine|May 4, 2025
Mechanism of action and future perspectives of ADCs in combination with immune checkpoint inhibitors for solid tumorsYahui Lv, Xiaoran Cui, Tao Li, et al.
Targeted Oncology|February 14, 2020
Tumor Mutation Burden as a Potential Biomarker for PD-1/PD-L1 Inhibition in Advanced Non-small Cell Lung CancerDi Huang, Fan Zhang, Haitao Tao, et al.
Clinical Medicine Insights. Oncology|March 19, 2021
The Synergistic Effect of PARP Inhibitors and Immune Checkpoint InhibitorsZhaozhen Wu, Pengfei Cui, Haitao Tao, et al.
Cancer Immunology, Immunotherapy : CII|March 19, 2021
Efficacy and safety of anti-PD-1-based therapy in combination with PARP inhibitors for patients with advanced solid tumors in a real-world settingZhaozhen Wu, Haitao Tao, Sujie Zhang, et al.
Pageof 6